Patents by Inventor Yayoi FUJIOKA

Yayoi FUJIOKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound
    Patent number: 11696917
    Abstract: To provide a method for treating cancer using a pyrazolo[3,4-d]pyrimidine compound or a salt thereof. The present invention provides an antitumor agent comprising a pyrazolo[3,4-d]pyrimidine compound of formula (I) wherein X, Y, Z1, Z2, Z3, Z4, W, n, R1, R2, and R3 have meanings as defined in the present specification, or a salt thereof and other antitumor agent(s) for combined administration.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: July 11, 2023
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiroki Irie, Kei Oguchi, Yayoi Fujioka
  • THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT
    Publication number: 20210252000
    Abstract: Provided is an anti-tumor agent for the treatment of a HER2-positive tumor that is tolerant to other anti-tumor agents or an intractable HER2-positive tumor. More specifically provided is a therapeutic agent for a HER2-positive tumor that is tolerant to other anti-tumor agents or an intractable HER2-positive tumor, which contains a pyrazolo[3,4-d]pyrimidine compound or a salt thereof as an active ingredient.
    Type: Application
    Filed: August 28, 2019
    Publication date: August 19, 2021
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiroki IRIE, Yayoi FUJIOKA
  • AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND
    Publication number: 20200061067
    Abstract: To provide a method for treating cancer using a pyrazolo[3,4-d]pyrimidine compound or a salt thereof. The present invention provides an antitumor agent comprising a pyrazolo[3,4-d]pyrimidine compound of formula (I) wherein X, Y, Z1, Z2, Z3, Z4, W, n, R1, R2, and R3 have meanings as defined in the present specification, or a salt thereof and other antitumor agent(s) for combined administration.
    Type: Application
    Filed: February 27, 2018
    Publication date: February 27, 2020
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiroki IRIE, Kei OGUCHI, Yayoi FUJIOKA